LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Akciju saraksts・Incyte Corp

Search

Incyte Corp

Slēgts

SektorsVeselības aprūpe

105.37 2.11

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

102.36

Max

110.19

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	14.215 49.052
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 368M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+6.93% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.1B 20B
Iepriekšējā atvēršanas cena	103.26
Iepriekšējā slēgšanas cena	105.37

Ziņu noskaņojums

By Acuity

32%

68%

81 / 344 Rangs Healthcare

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. jūn. 23:36 UTC

Peļņas

Correction to Oracle Reports Higher 4Q Profit Article

2026. g. 10. jūn. 23:19 UTC

Karstas akcijas

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026. g. 10. jūn. 23:09 UTC

Galvenie tirgus virzītāji

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026. g. 10. jūn. 23:04 UTC

Peļņas

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026. g. 10. jūn. 20:44 UTC

Galvenie tirgus virzītāji

Caterpillar Raises Quarterly Dividend 8%

2026. g. 10. jūn. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Northern Star Should Take No Options Off The Table

2026. g. 10. jūn. 23:48 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026. g. 10. jūn. 23:48 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026. g. 10. jūn. 23:47 UTC

Tirgus saruna

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026. g. 10. jūn. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026. g. 10. jūn. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026. g. 10. jūn. 23:32 UTC

Tirgus saruna

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026. g. 10. jūn. 23:20 UTC

Tirgus saruna

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026. g. 10. jūn. 22:05 UTC

Tirgus saruna

Correction to Bank of Canada Stays on Hold Market Talk

2026. g. 10. jūn. 21:57 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:52 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:35 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:22 UTC

Peļņas

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. jūn. 20:39 UTC

Tirgus saruna

Peļņas

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026. g. 10. jūn. 20:34 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

Peļņas

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 20:33 UTC

Tirgus saruna

Peļņas

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

6.93% augšup

Prognoze 12 mēnešiem

Vidējais 110.38 USD 6.93%

Augstākais 140 USD

Zemākais 75 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

8

Pirkt

10

Turēt

1

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

81 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Citi krājumi no sektora

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat